Animalcare (ANCR) AI Stock Analysis

• Market Cap: £195.40M
• Dividend Yield: 2.18%
• Average Volume (3M): 66.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.31
• Revenue Growth: 8.74%
• EPS Growth: -166.50%
• Country: UK
• Employees: 226
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.10
• Shares Outstanding: 69,045,944
• 10 Day Avg. Volume: 79,363
• 30 Day Avg. Volume: 66,930
• PEG Ratio: <0.01
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 2.01
• P/FCF Ratio: 12.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: 307.00p ▲(28.99% Upside)

Animalcare's overall stock score reflects strong financial stability and positive corporate events, which are offset by valuation concerns due to a negative P/E ratio. Technical indicators suggest moderate potential for price appreciation. The company's strategic initiatives and director's confidence are significant positives.

Positive Factors

Balance sheet strength

A high equity ratio and minimal leverage provide durable financial flexibility to fund R&D, acquisitions, and operational needs without heavy reliance on external debt. This reduces refinancing risk, supports creditworthiness, and underpins strategic execution over the next several quarters.

High and improving margins

Sustained gross (~45.9%) and sharply improved net margins (43.4%) indicate pricing power, efficient production and cost control. High margins create durable cash buffers for reinvestment, support margin-accretive growth, and increase resilience to input cost volatility.

Strong cash generation

Robust free cash flow growth (51.7%) and solid operating cash conversion show the business reliably converts profits into cash. This enables self-funding of capex, dividends or M&A, reducing dependence on external financing and supporting sustainable strategic initiatives.

Negative Factors

Recent revenue contraction

A slight revenue decline and negative year-over-year growth risk eroding scale benefits and hindering market-share expansion. Persistent top-line weakness can limit reinvestment capacity for R&D, marketing, and distribution expansion, pressuring medium-term growth prospects.

Rising total liabilities

Growing total liabilities, if unchecked, may increase fixed obligations and reduce balance sheet flexibility. Even from a low leverage base, rising liabilities can elevate refinancing and interest risks, constraining capital allocation and strategic options over the medium term.

Negative EPS growth

Significant negative EPS growth points to earnings volatility or one-off charges that undermine per-share profitability. This can limit the company's ability to sustain dividends, reinvest internally, and may impede confidence in long-term earnings quality absent a clear recovery path.

Animalcare Business Overview & Revenue Model

Company Description

Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets. It is also involved in the wholesale and marketing of veterinary pharmaceuticals. The company serves customers in Belgium, the Netherlands, the United Kingdom, Germany, Spain, Italy, Portugal, other European countries, Asia, the Middle East, Africa, and internationally. Animalcare Group plc was incorporated in 1972 and is based in York, the United Kingdom.

How the Company Makes Money

Animalcare generates revenue through multiple streams, primarily by selling its veterinary pharmaceuticals and products to veterinary practices, pet owners, and livestock producers. The company has established a strong presence in the European market and partners with various distributors to enhance its product reach. Significant revenue is also derived from the sale of diagnostic tools and services that assist veterinarians in the treatment and management of animal health. Additionally, Animalcare invests in research and development to innovate and expand its product portfolio, which can lead to increased market share and revenue growth. Collaborations with research institutions and other healthcare companies further support its revenue generation efforts.

Animalcare Financial Statement Overview

Summary

Animalcare exhibits strong financial stability with a high equity ratio and low debt-to-equity ratio, indicating minimal financial risk. The company has improved its net profit margin and return on equity, although revenue contraction poses a challenge. Cash flow generation remains robust, supporting operational strategies despite rising liabilities.

Income Statement

Animalcare has demonstrated stable revenue with a slight decrease in 2024. The gross profit margin remains strong at around 45.9% in 2024, reflecting efficient production. The net profit margin has significantly improved from previous years, reaching 43.4% in 2024, due to increased net income influenced by effective cost management. However, the revenue growth rate is negative over the past year, indicating a potential challenge in expanding market share.

Balance Sheet

The balance sheet shows a healthy equity ratio of 71.3% in 2024, indicating strong financial stability. The debt-to-equity ratio is low at 0.20, reflecting minimal leverage and low financial risk. Return on equity improved drastically to 28.4% in 2024, demonstrating enhanced profitability. However, the increase in total liabilities over the years could pose future risks if not managed effectively.

Cash Flow

Animalcare's cash flow statements reveal consistent free cash flow generation, with a growth rate of 51.7% from 2023 to 2024, supporting financial flexibility. The operating cash flow to net income ratio is robust at 0.37, indicating good cash conversion. However, the free cash flow to net income ratio is slightly lower at 0.36, suggesting some inefficiencies in cash utilization relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	81.07M	74.23M	74.35M	71.62M	74.02M	70.49M
Gross Profit	37.52M	34.06M	43.35M	40.66M	39.42M	36.56M
EBITDA	14.03M	13.43M	11.82M	11.04M	10.15M	10.30M
Net Income	2.98M	32.22M	1.20M	1.97M	-77.00K	234.00K
Balance Sheet
Total Assets	163.87M	158.81M	106.79M	118.24M	110.00M	124.44M
Cash, Cash Equivalents and Short-Term Investments	9.92M	11.71M	4.64M	6.04M	5.63M	5.26M
Total Debt	21.02M	24.01M	5.88M	11.44M	10.96M	18.88M
Total Liabilities	50.62M	45.50M	28.90M	39.26M	31.20M	42.84M
Stockholders Equity	113.25M	113.31M	77.89M	78.99M	78.80M	81.59M
Cash Flow
Free Cash Flow	11.12M	11.72M	7.73M	6.48M	10.81M	8.68M
Operating Cash Flow	11.41M	11.93M	10.28M	9.43M	14.02M	11.12M
Investing Cash Flow	-63.51M	-34.85M	-2.86M	-3.12M	-2.96M	-2.91M
Financing Cash Flow	29.22M	32.53M	-8.95M	-5.70M	-10.96M	-8.86M

Animalcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 238.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANCR, the sentiment is Positive. The current price of 238 is below the 20-day moving average (MA) of 256.35, below the 50-day MA of 248.16, and below the 200-day MA of 254.77, indicating a bullish trend. The MACD of 7.77 indicates Negative momentum. The RSI at 89.07 is Negative, neither overbought nor oversold. The STOCH value of 87.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ANCR.

Animalcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	76 Outperform	£76.23M	25.22	3.62%	―	1.44%	359.79%
ANCR	67 Neutral	£195.40M	-7.98	2.83%	2.18%	8.74%	-166.50%
VLG	65 Neutral	£82.75M	―	―	―	―	―
STX	63 Neutral	£114.81M	-5.78	-396.71%	―	93.48%	51.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Animalcare Corporate Events

Animalcare posts strong 2025 growth on Randlab deal and flagship brands

Animalcare reported a strong 2025 trading performance, with revenues up 20% to about £89.1m and underlying EBITDA rising roughly 50%, driven by the successful acquisition and integration of Randlab, double‑digit growth in flagship companion animal brands such as Daxocox, and a sharply expanded equine franchise that now accounts for nearly a quarter of group sales. The company underscored its solid balance sheet and cash generation, continued execution across its three strategic pillars of organic growth, M&A and new product development, and a bolstered R&D pipeline of five key projects including the VHH NGF antibody programme and a new equine biologics technology licence, positioning the Group for accelerated, sustainable growth and setting the stage for a March capital markets event to showcase its plans to investors.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £270.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Grants New LTIP Share Options to Senior Executives

Animalcare Group has granted nil-cost options over 294,222 ordinary shares to its executive directors and other persons discharging managerial responsibilities under its Long Term Incentive Plan, marking the only such awards to executives in the 2025 financial year. The three-year awards, split evenly between earnings per share growth and relative total shareholder return performance conditions, are designed to align leadership incentives with shareholder value creation through to the end of 2027, with the company signalling a move to making future grants earlier in the year, typically in May, which may improve transparency and predictability for investors monitoring its remuneration and governance practices.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £270.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Director Increases Stake with Share Purchase

Animalcare Group plc announced that Dr. Douglas Hutchens, a Non-Executive Director, purchased 7,500 ordinary shares at 249p each, increasing his total interest to 12,500 shares, representing 0.02% of the company’s voting rights. This transaction, conducted on the London Stock Exchange’s AIM, reflects Dr. Hutchens’ confidence in the company’s strategic direction and may positively influence stakeholder perceptions of Animalcare’s market positioning.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £268.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Animalcare Group Announces New Share Issuance Following Option Exercise

Animalcare Group plc announced the exercise of options under its Long Term Incentive Plan, resulting in the issuance of 56,873 new ordinary shares. These shares are expected to begin trading on AIM on 24 November 2025 and will have equal rights with existing shares, including dividend entitlements. Following this issuance, the total number of ordinary shares with voting rights will be 69,045,945, which shareholders can use to assess their interest in the company’s share capital under FCA rules.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £268.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.